Tumour necrosis factor blockade and the risk of osteoporosis back to the future 英文参考文献.docVIP

Available online /content/9/4/107 Editorial Tumour necrosis factor blockade and the risk of osteoporosis: back to the future Philip Sambrook Kolling Institute, University of Sydney, Sydney, Australia Corresponding author: Philip Sambrook, sambrook@.au Published: 30 August 2007 Arthritis Research Therapy 2007, 9:107 (doi:10.1186/ar2277) This article is online at /content/9/4/107 ? 2007 BioMed Central Ltd See related research article by Marotte et al., /content/9/3/R61 Abstract RANKL with RANK and thus acts as a physiological regulator of bone turnover. These observations suggest that TNF blockade may have a beneficial effect on bone generally, not just on erosions in RA. Osteoporosis is a common clinical problem, especially in patients with rheumatoid arthritis (RA). A reduction in bone mineral density (BMD) of the axial and appendicular skeleton ranging from 7% to 15% has been reported in RA in studies employing a variety of densitometric techniques. Reports consistent with a beneficial effect of tumour necrosis factor blockade on BMD have begun to emerge in recent years, and in Arthritis Research and Therapy, a case control study reports that patients treated with infliximab for RA had preservation of BMD in the lumbar spine and femoral neck compared to those treated with methotrexate. In the previous issue of Arthritis Research and Therapy, Marotte and colleagues [6] reported a case control study in 99 patients with RA treated with infliximab. After 12 months, patients receiving infliximab had preservation of bone mineral density (BMD) in the lumbar spine and femoral neck whereas bone loss amounting to 3.9% and 2.5% was observed at the same sites, respectively, in the control group treated with methotrexate alone. Changes in biochemical markers of bone turnover from baseline or between the groups were not statistically different. However, the trends